AR009543A1 - Fragmento estructural derivado del acido carbonico, derivados que lo incluyen, metodo de preparacion de derivado utiles como material de partida yuso de dichos derivados. - Google Patents
Fragmento estructural derivado del acido carbonico, derivados que lo incluyen, metodo de preparacion de derivado utiles como material de partida yuso de dichos derivados.Info
- Publication number
- AR009543A1 AR009543A1 ARP970104059A ARP970104059A AR009543A1 AR 009543 A1 AR009543 A1 AR 009543A1 AR P970104059 A ARP970104059 A AR P970104059A AR P970104059 A ARP970104059 A AR P970104059A AR 009543 A1 AR009543 A1 AR 009543A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compounds
- hydroxy
- halogen
- formula
- Prior art date
Links
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 239000007858 starting material Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- -1 nitro, cyano, hydroxy, mercapto Chemical class 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Chemical group 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen un fragmento derivado del ácido carbonico de formula (Ia) y derivados de ácido carbonico de la formula (I), en donde R1 es tetrazol o a ungrupo, R2 es hidrogeno, hidroxi, NH2, NH(C1-C4-alquilo), N(C1-C4-alquilo)2, halogeno, C1-C4-alquilo, etc.; X e Y nitrogeno, o metilo; Z es nitrogeno oCR10. Por lo menos uno de los eslabones del ciclo X, Y o Z es nitrogeno; R3 es hidrogeno, hidroxi, NH2, NH(C1-C4-alquilo), N(C1-C4-alquilo)2, halogeno,C1-C4-alquilo, etc.; R4 y R5 (que pueden ser iguales o distintos)son: fenilo o naftilo que pueden ser sustituidos por uno o más de los siguientes residuos:halogeno, nitro, ciano, hidroxi, mercapto, C1-C4-alquilo, etc.; R6 es C3-C8- cicloalquilo, en donde estos residuos pueden sersustituidos una o más vecespor: halogeno, hidroxi, mercapto, carboxi, nitro, ciano, C1-C4-alcoxi, C1-C4-alquilo, etc.; W es azufre u oxígeno; Q es un distanciador que en sulargo corresponda a una cadena C2-C4. La funcion de Q es producir enlos compuestos de la formula (I) una distancia definida entre los grupos R6 y W.También son objeto aquellos compuestos de los que se liberan los compuestos de la formula (I) (las denominadas prodrogas). Se prefieren aquellas prodrogasen las que la liberacion sucede bajo tales condiciones, como las que prevalecen en determinados compartimientos corporales, por ejemplo, el estomago, elintestino, la circulacion sanguínea, el hígado. Los compuestos y también los productos intermedios para su fabricacion, como por ejemplo (II), (III) y (IV)pueden poseer uno o más átomos de carbono sustituidos asimétricamente. Estos compuestos pueden presentarse como enantiomeros puros o diastereomeros puroso como combinacion de ellos. Se prefiere la aplicacion de un compuesto de enantiomeros puros como sustancia activa. Tambiém se describe la utilizacion
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19636046A DE19636046A1 (de) | 1996-09-05 | 1996-09-05 | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009543A1 true AR009543A1 (es) | 2000-04-26 |
Family
ID=7804712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970104059A AR009543A1 (es) | 1996-09-05 | 1997-09-05 | Fragmento estructural derivado del acido carbonico, derivados que lo incluyen, metodo de preparacion de derivado utiles como material de partida yuso de dichos derivados. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6670367B1 (es) |
| EP (1) | EP0929529A2 (es) |
| JP (1) | JP2000517329A (es) |
| KR (1) | KR20000068446A (es) |
| CN (1) | CN1236362A (es) |
| AR (1) | AR009543A1 (es) |
| AU (1) | AU736414B2 (es) |
| BG (1) | BG103258A (es) |
| BR (1) | BR9711693A (es) |
| CA (1) | CA2265504A1 (es) |
| CO (1) | CO4900070A1 (es) |
| DE (1) | DE19636046A1 (es) |
| HU (1) | HUP0000664A3 (es) |
| ID (1) | ID19417A (es) |
| IL (1) | IL128743A0 (es) |
| NO (1) | NO312674B1 (es) |
| NZ (1) | NZ334548A (es) |
| PL (1) | PL331998A1 (es) |
| SK (1) | SK25999A3 (es) |
| TR (1) | TR199900486T2 (es) |
| WO (1) | WO1998009953A2 (es) |
| ZA (1) | ZA977946B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030975A (en) * | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
| CN1269792A (zh) * | 1997-09-04 | 2000-10-11 | Basf公司 | 新羧酸衍生物,它们的制备方法和作为混合eta/etb受体拮抗药的用途 |
| DE59810600D1 (de) * | 1997-09-26 | 2004-02-19 | Abbott Gmbh & Co Kg | Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate |
| DE19743143A1 (de) * | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| AU742506B2 (en) * | 1997-10-17 | 2002-01-03 | Eurogene Limited | The use of inhibitors of the renin-angiotensin system |
| DE19809144A1 (de) * | 1998-03-04 | 1999-09-09 | Basf Ag | Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten |
| DE19836044A1 (de) * | 1998-08-10 | 2000-02-17 | Basf Ag | Neue Carbonsäurederivate, die Ketoseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| DE19933164A1 (de) * | 1999-07-20 | 2001-01-25 | Basf Ag | Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten |
| DE19951671A1 (de) * | 1999-10-27 | 2001-05-03 | Basf Ag | 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist |
| DE10064797A1 (de) * | 2000-12-22 | 2002-06-27 | Knoll Ag | Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon |
| JP4155561B2 (ja) * | 2000-12-26 | 2008-09-24 | 国立大学法人佐賀大学 | アレルギー性疾患検査方法 |
| PT1243262E (pt) | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
| DK1243263T3 (da) | 2001-03-21 | 2003-03-17 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte |
| CN1950101B (zh) | 2004-04-16 | 2011-03-30 | 舒沃茨药物股份公司 | 肽化合物用于预防和治疗慢性头痛的用途 |
| EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| KR20070045271A (ko) | 2004-08-27 | 2007-05-02 | 쉬바르츠파르마에이지 | 골암 통증, 화학요법- 및 뉴클레오시드- 유도 통증의치료를 위한 펩티드 화합물의 용도 |
| CA2646438A1 (en) * | 2006-03-13 | 2007-09-20 | Encysive Pharmaceuticals, Inc. | Methods and compositions for treatment of diastolic heart failure |
| AU2007225207A1 (en) * | 2006-03-13 | 2007-09-20 | Encysive Pharmaceuticals, Inc. | Formulations of sitaxsentan sodium |
| EP2992891B1 (en) | 2006-06-15 | 2020-08-05 | UCB Pharma GmbH | Pharmaceutical composition comprising brivaracetam and lacosamide with synergistic anticonvulsant effect |
| US20080026061A1 (en) * | 2006-06-22 | 2008-01-31 | Reichwein John F | Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide |
| CN103709106A (zh) * | 2013-12-06 | 2014-04-09 | 石家庄博策生物科技有限公司 | 一种立体选择性制备安立生坦的方法 |
| CN103739557B (zh) * | 2013-12-30 | 2015-10-21 | 黄河三角洲京博化工研究院有限公司 | 一种4,6-二甲基-2-甲磺酰基嘧啶的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4313412A1 (de) * | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| DE4313413A1 (de) * | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryloxy(thio)-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| DE4335950A1 (de) | 1993-10-21 | 1995-04-27 | Basf Ag | Derivate von 3-Hydroxycarbonsäuren, deren Herstellung und Verwendung |
| DE4411225A1 (de) | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
| DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DE19536891A1 (de) | 1995-10-04 | 1997-04-10 | Basf Ag | Neue Aminosäurederivate, ihre Herstellung und Verwendung |
-
1996
- 1996-09-05 DE DE19636046A patent/DE19636046A1/de not_active Withdrawn
-
1997
- 1997-03-02 US US09/254,137 patent/US6670367B1/en not_active Expired - Fee Related
- 1997-09-02 BR BR9711693A patent/BR9711693A/pt not_active IP Right Cessation
- 1997-09-02 JP JP10512203A patent/JP2000517329A/ja active Pending
- 1997-09-02 HU HU0000664A patent/HUP0000664A3/hu unknown
- 1997-09-02 CN CN97199458A patent/CN1236362A/zh active Pending
- 1997-09-02 NZ NZ334548A patent/NZ334548A/xx unknown
- 1997-09-02 PL PL97331998A patent/PL331998A1/xx unknown
- 1997-09-02 AU AU45524/97A patent/AU736414B2/en not_active Ceased
- 1997-09-02 TR TR1999/00486T patent/TR199900486T2/xx unknown
- 1997-09-02 IL IL12874397A patent/IL128743A0/xx unknown
- 1997-09-02 KR KR1019997001815A patent/KR20000068446A/ko not_active Ceased
- 1997-09-02 WO PCT/EP1997/004688 patent/WO1998009953A2/de not_active Ceased
- 1997-09-02 CA CA002265504A patent/CA2265504A1/en not_active Abandoned
- 1997-09-02 EP EP97943819A patent/EP0929529A2/de not_active Withdrawn
- 1997-09-02 SK SK259-99A patent/SK25999A3/sk unknown
- 1997-09-04 CO CO97051479A patent/CO4900070A1/es unknown
- 1997-09-04 ZA ZA977946A patent/ZA977946B/xx unknown
- 1997-09-05 AR ARP970104059A patent/AR009543A1/es not_active Application Discontinuation
- 1997-09-05 ID IDP973110A patent/ID19417A/id unknown
-
1999
- 1999-03-04 NO NO19991079A patent/NO312674B1/no not_active IP Right Cessation
- 1999-03-16 BG BG103258A patent/BG103258A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL128743A0 (en) | 2000-01-31 |
| CA2265504A1 (en) | 1998-03-12 |
| NO991079L (no) | 1999-05-04 |
| NO312674B1 (no) | 2002-06-17 |
| NO991079D0 (no) | 1999-03-04 |
| NZ334548A (en) | 2000-09-29 |
| BG103258A (en) | 2000-12-29 |
| SK25999A3 (en) | 1999-09-10 |
| DE19636046A1 (de) | 1998-03-12 |
| WO1998009953A2 (de) | 1998-03-12 |
| AU736414B2 (en) | 2001-07-26 |
| HUP0000664A3 (en) | 2001-07-30 |
| PL331998A1 (en) | 1999-08-16 |
| CN1236362A (zh) | 1999-11-24 |
| ZA977946B (en) | 1999-03-04 |
| KR20000068446A (ko) | 2000-11-25 |
| ID19417A (id) | 1998-07-09 |
| CO4900070A1 (es) | 2000-03-27 |
| TR199900486T2 (xx) | 1999-06-21 |
| WO1998009953A3 (de) | 1998-10-29 |
| JP2000517329A (ja) | 2000-12-26 |
| HUP0000664A2 (hu) | 2001-04-28 |
| US6670367B1 (en) | 2003-12-30 |
| AU4552497A (en) | 1998-03-26 |
| EP0929529A2 (de) | 1999-07-21 |
| BR9711693A (pt) | 1999-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR009543A1 (es) | Fragmento estructural derivado del acido carbonico, derivados que lo incluyen, metodo de preparacion de derivado utiles como material de partida yuso de dichos derivados. | |
| LU88769I2 (fr) | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) | |
| PE20020532A1 (es) | Derivados de naftaleno como agonistas del receptor canabinoide | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| AR009357A1 (es) | Compuesto de amidas de acido fosfinico y sus usos para preparar una composicion farmaceutica y en un metodo para prevenir o tratar unaenfermedad asociada a la actividad de metaloproteasa | |
| ITMI922006A1 (it) | Esteri nitrici di derivati dell'acido 2-(2, 6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
| PE20030612A1 (es) | Benzoimidazoles | |
| PE20011314A1 (es) | DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA | |
| TR200000670T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
| TR200000671T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler. | |
| TR200000673T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
| PE20091443A1 (es) | Derivados bis-(sulfonilamino) como inhibidores de la enzima prostaglandina e sintasa-1 microsomal | |
| PE20050131A1 (es) | Derivados de benzoimidazol como agentes antiproliferativos | |
| GT200300240A (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos | |
| PA8610801A1 (es) | Compuestos de aril o heteroaril amida | |
| TR200100410T2 (tr) | 2-(purin-9-il)-tetrahidrofuran-3,4-diol türevleri. | |
| PE20030976A1 (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| HUP0002122A2 (hu) | Ciklusos tio-szubsztituált acilaminosav-amid származékok | |
| PE20030944A1 (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
| PT1202957E (pt) | Aminobenzofenonas como inibidoras de il-1beta e tnf-alpha | |
| PE20050035A1 (es) | COMPUESTOS DE FENILINDOL PARA MODULAR LA IgE E INHIBIR LA PROLIFERACION CELULAR | |
| ES8301210A1 (es) | Un procedimiento para la preparacion de un derivado del indol. | |
| AR041861A1 (es) | Feniliso (tio) cianatos, procesos e intermediarios para su preparacion. | |
| AR008621A1 (es) | Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto | |
| ES8601184A1 (es) | Procedimiento para la preparacion de derivados de pirimidina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |